Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | FABP1 | P07148 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | LIFR | P42702 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347350 | 0.95 | NR1H4 (0.67) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL12932245 | 0.94 | NR1H4 (0.81) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL18347351 | 0.92 | NR1H4 (0.63) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL14601398 | 0.90 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16917082 | 0.88 | NR1H4 (0.77) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16917074 | 0.86 | NR1H4 (0.77) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL19760093 | 0.86 | NR1H4 (0.56) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL13805380 | 0.86 | NR1H4 (0.79) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 0.84 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996233 | 0.84 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| US-20110021475-A1 | Compositions And Methods for Treatment Of Fibrosis | JONES STACEY ANN | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NR1H4 10/4885MEN1 2508/4885FABP1 18/4885 |
| US-20110021475-A1 | Compositions And Methods for Treatment Of Fibrosis | NR1H4, FABP1, SLC10A1 | NR1H4 1/4885MEN1 4824/4885FABP1 2/4885 |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885MEN1 4283/4885FABP1 10/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885MEN1 4525/4885FABP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.